The diagnosis of systemic mastocytosis depends partly on finding mast cell infiltration of extracutaneous tissue. The bone marrow commonly is chosen as the site for biopsy. In addition to systemic mastocytosis, an increase in bone marrow mast cells may accompany such hematologic disorders as chronic lymphocytic leukemia, non-Hodgkin lymphoma, 1 dysmyelopoiesis, and myeloproliferative disorders. 2 Hence, in the evaluation of a patient for systemic mastocytosis, bone marrow aspiration and biopsy serve 2 purposes: to confirm the diagnosis of mastocytosis and to evaluate the bone marrow for associated hematologic disorders. The number of mast cells detected in bone marrow samples has been shown to correlate positively with the urinary excretion of tele-methylimidazoleacetic acid, the primary histamine metabolite. 3 Although skeletal scintigraphic findings in mastocytosis might show multifocal or diffuse abnormalities, the radionuclide bone patterns might be normal or show only unifocal involvement. 4 Also, only patchy or focal infiltration patterns involving peritrabecular or perivascular regions or areas around lymphoid aggregates might be evident, rather than diffuse infiltration. 5 To determine whether the presence of mastocytosis could be missed because of sampling error, we retrospectively reviewed the findings in each of the bilateral biopsy sites of 21 patients who had been evaluated for systemic mastocytosis during the previous 5 years and 2 patients with known disease with bilateral biopsies at the time of follow-up.
Materials and Methods
The medical records of patients with the diagnosis of systemic mastocytosis who had bilateral biopsies performed during their evaluation or follow-up during the past 5 years were selected for retrospective review. Patients who had undergone only a unilateral biopsy (with positive or negative results for systemic mastocytosis) were not included.
Slides from each bone marrow biopsy specimen were examined for the presence of mastocytosis by a hematopathologist (C.-Y.L.) and classified according to the World Health Organization (WHO) criteria. 6 Bone marrow biopsy specimens were stained routinely for the presence of mast cells with an immunohistochemical stain for tryptase. 7 The presence or absence of mast cell infiltrates was assessed in the left-and right-sided specimens, and the percentage of involvement was estimated by direct visualization.
The following laboratory results were compared between the group with bilaterally positive results of bone marrow biopsies and the group with a positive bone marrow biopsy result in only 1 of 2 sites: alkaline phosphatase, aspartate transaminase, and hemoglobin concentrations; total leukocyte, total eosinophil, and platelet counts; serum tryptase and serum calcitonin concentrations; and 24-hour urinary excretion of 11β-prostaglandin F 2α . Any available bone scan and bone radiographic reports also were reviewed and compared.
Statistical Analysis
The Mann-Whitney test was used to determine the statistical significance of comparisons between laboratory results for patients with bilateral bone marrow involvement and for patients with unilateral involvement. The InStat 2.03 computer program (GraphPad Software, San Diego, CA) was used.
Results
The initial complaint(s), percentage of bone marrow involved, presence or absence of splenomegaly and urticaria pigmentosa, serum tryptase level, and the WHO classification for each patient are listed in ❚Table 1❚, and hematologic findings are listed in ❚Table 2❚. Mast cell involvement was present bilaterally in 19 (83%) of 23 patients. In each of the other 4 patients with only unilateral involvement, the percentage of bone marrow involvement was low (≤5%), and each case was classified as indolent systemic mastocytosis. None of the patients with unilateral involvement had splenomegaly, but 7 (37%) of 19 with bilateral involvement had splenomegaly or hepatosplenomegaly. Of the laboratory studies performed, the urinary excretion of 11β-prostaglandin F 2α (1-tailed P = .0109), total tryptase concentration (1-tailed P = .0329), and plasma calcitonin concentration (1-tailed P = .0403) were significantly higher in the group with bilateral involvement. Differences in the mean platelet counts between the bilateral and unilateral groups did not quite reach statistical significance (P = .0582). The presence of urticaria pigmentosa was almost equal in the bilateral (9/19 [47%]) and unilateral (2/4 [50%]) groups.
For the patients with unilaterally positive bone marrow biopsy results, bone scans had not been performed. Two bone scans had been performed in the group with bilaterally positive bone marrow biopsy results; the results were normal in 1 patient (case 7) and showed multiple foci of increased radiotracer uptake in the axial and appendicular skeleton in another patient (case 18). Metastatic bone surveys in 2 patients with unilateral findings showed generalized demineralization (case 1), degenerative arthritic changes (case 5), and mild compression fractures of vertebral bodies (cases 1 and 5). In the group with bilaterally positive results, plain radiographs were remarkable primarily for sclerotic changes in the bones examined: lumbar spine and pelvis (case 13), hips (case 14), and diffuse sclerosis (metastatic survey) (case 18).
Discussion
The diagnosis of systemic mastocytosis can be overlooked for many years because symptoms may progress slowly. Also, the initial clinical signs are potentially numerous and might include constitutional symptoms, anaphylaxis, dermatologic findings, or various organ system signs due to mast cell mediator release. 8 At present, the diagnosis depends on a high level of clinical suspicion in combination with appropriate clinical and laboratory findings. Among these tests, positive findings in bone marrow biopsy specimens are necessary to make an unequivocal diagnosis. Several classifications of mastocytosis, including the new WHO classification, have been suggested, 6,9-11 but until a tissue diagnosis has been established, these are not helpful to a clinician faced with a patient who has a confusing array of symptoms. Mastocytosis may present without accompanying urticaria pigmentosa, 12,13 thus potentially prolonging the time to diagnosis.
Tryptase values are helpful in the diagnosis of systemic mastocytosis, although the absolute value of total tryptase does not seem to predict the clinical severity of mastocytosis. 14 In 1 report, the prevalence of positive bone marrow biopsy results for mastocytosis increased, as did the total tryptase value. Patients with serum tryptase values of more than 75 ng/mL had biopsy results that were 100% positive, whereas in those with tryptase values between 20 and 75 ng/mL, 50% were positive. 15 Possibly some of the latter group could have been found positive for mastocytosis if bilateral biopsies had been done. In our study, 3 of 4 patients with mastocytosis and only a unilaterally positive biopsy result had serum tryptase values of less than 25 ng/mL; thus, they would not have been given a diagnosis of mastocytosis if tryptase values had been used as the sole criterion for screening. In the group with bilaterally positive biopsy results, the tryptase values were higher, but 4 of 19 had tryptase values of less than 25 ng/mL, and 1 additional patient had a borderline value, at 29 ng/mL. In addition, elevated tryptase values are not specific for mastocytosis because they also may be detected in myelodysplastic syndromes. 16 Previous experiences in lymphoma staging have indicated that the yield of demonstrable marrow involvement with lymphoma is increased significantly when bilateral biopsies are performed. Bilateral bone marrow biopsies, which provide more tissue for examination and sample 2 separate sites, were recommended for that purpose. 17, 18 Our results suggest that early mastocytosis, even in patients with suggestive symptoms, might be missed when bone marrow biopsy is performed only unilaterally.
